Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Healthtrust
Federal Trade Commission
Harvard Business School
Citi
Teva
Julphar
Express Scripts
Medtronic

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,226,931

« Back to Dashboard

Which drugs does patent 9,226,931 protect, and when does it expire?

Patent 9,226,931 protects LATISSE and is included in one NDA.

This patent has sixteen patent family members in seven countries.
Summary for Patent: 9,226,931
Title:Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
Inventor(s): Ahluwalia; Gurpreet (Orange, CA), Beddingfield; Frederick C. (Pacific Palisades, CA), Edwards; Sydney G. (Aliso Viejo, CA), Whitcup; Scott M. (Laguna Hills, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:14/199,402
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 9,226,931

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,226,931

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,758,733 Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists ➤ Sign Up
8,101,161 Method of enhancing hair growth ➤ Sign Up
7,351,404 Method of enhancing hair growth ➤ Sign Up
8,632,760 Method of enhancing hair growth ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,226,931

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013208002 ➤ Sign Up
Canada 2475106 ➤ Sign Up
European Patent Office 1471876 ➤ Sign Up
European Patent Office 2250996 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Mallinckrodt
Teva
Fuji
US Army
McKesson
Citi
Chinese Patent Office
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.